Literature DB >> 22946665

Role of interleukin-10 in the regulation of tumorigenicity of a T cell lymphoma.

Mona R Hassuneh1, Mitzi Nagarkatti, Prakash S Nagarkatti.   

Abstract

Interleukin-10 (IL-10) is a cytokine that is produced by a variety of immune cells and is known to inhibit T helper cell type 1 (T(H)1) responses, which are essential to combat tumors. In the present study, we used LSA, a T cell lymphoma cell line that expresses IL-10, to study the role of this cytokine in its tumorigenesis. To this end, LSA cells were modified to overexpress IL-10 or to block its expression via Ret-off-IL-10 vector transfection. Interestingly, blocking IL-10 expression using Ret-off-IL-10 antisense inhibited the growth of LSA in syngeneic C57BL/6 mice. Also, overexpression of IL-10 in LSA cells using Ret-off-IL-10 sense significantly increased LSA tumorigenicity. Additionally, administration of antibodies against IL-10 significantly inhibited LSA tumor growth in vivo. Together, our data stress the importance of tumor-produced IL-10 in regulating the tumorigenicity of this T cell lymphoma, and suggest that antagonizing IL-10 expression in IL-10 secreting lymphomas may have significant potential in their treatment.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 22946665      PMCID: PMC4156858          DOI: 10.3109/10428194.2012.726721

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN: 1026-8022


  52 in total

Review 1.  Control of intestinal inflammation by regulatory T cells.

Authors:  B Singh; S Read; C Asseman; V Malmström; C Mottet; L A Stephens; R Stepankova; H Tlaskalova; F Powrie
Journal:  Immunol Rev       Date:  2001-08       Impact factor: 12.988

2.  Immunomodulation by various nitrosoureas and its effect on the survival of the murine host bearing a syngeneic tumor.

Authors:  M Nagarkatti; D M Toney; P S Nagarkatti
Journal:  Cancer Res       Date:  1989-12-01       Impact factor: 12.701

Review 3.  Interleukin-10 and the interleukin-10 receptor.

Authors:  K W Moore; R de Waal Malefyt; R L Coffman; A O'Garra
Journal:  Annu Rev Immunol       Date:  2001       Impact factor: 28.527

4.  Serum interleukin-10 but not interleukin-6 is related to clinical outcome in patients with resectable hepatocellular carcinoma.

Authors:  G Y Chau; C W Wu; W Y Lui; T J Chang; H L Kao; L H Wu; K L King; C C Loong; C Y Hsia; C W Chi
Journal:  Ann Surg       Date:  2000-04       Impact factor: 12.969

5.  Studies of the LSA ascites lymphoma of C57BL mice. I. Transplantation characteristics and radiosensitivity of cells during serial passages.

Authors:  G Silini; Y Maruyama
Journal:  J Natl Cancer Inst       Date:  1965-11       Impact factor: 13.506

6.  Comparison of serum interleukin-10 (IL-10) levels between normal volunteers and patients with advanced melanoma.

Authors:  J Nemunaitis; T Fong; P Shabe; D Martineau; D Ando
Journal:  Cancer Invest       Date:  2001       Impact factor: 2.176

7.  Isolation and expression of human cytokine synthesis inhibitory factor cDNA clones: homology to Epstein-Barr virus open reading frame BCRFI.

Authors:  P Vieira; R de Waal-Malefyt; M N Dang; K E Johnson; R Kastelein; D F Fiorentino; J E deVries; M G Roncarolo; T R Mosmann; K W Moore
Journal:  Proc Natl Acad Sci U S A       Date:  1991-02-15       Impact factor: 11.205

8.  The role of suppressor T cells in BCNU-mediated rejection of a syngeneic tumor.

Authors:  M Nagarkatti; A M Kaplan
Journal:  J Immunol       Date:  1985-08       Impact factor: 5.422

9.  Characterization of tumor-infiltrating CD4+ T cells as Th1 cells based on lymphokine secretion and functional properties.

Authors:  M Nagarkatti; S R Clary; P S Nagarkatti
Journal:  J Immunol       Date:  1990-06-15       Impact factor: 5.422

10.  Two types of mouse T helper cell. IV. Th2 clones secrete a factor that inhibits cytokine production by Th1 clones.

Authors:  D F Fiorentino; M W Bond; T R Mosmann
Journal:  J Exp Med       Date:  1989-12-01       Impact factor: 14.307

View more
  6 in total

1.  Increased serum levels of interleukin-10 predict poor prognosis in extranodal natural killer/T-cell lymphoma patients receiving asparaginase-based chemotherapy.

Authors:  Hua Wang; Liang Wang; ZhiJun Wuxiao; HuiQiang Huang; WenQi Jiang; ZhiMing Li; Yue Lu; ZhongJun Xia
Journal:  Onco Targets Ther       Date:  2015-09-14       Impact factor: 4.147

2.  Interleukin-10 deficiency impairs regulatory T cell-derived neuropilin-1 functions and promotes Th1 and Th17 immunity.

Authors:  Shimin Wang; Xiang Gao; Guobo Shen; Wei Wang; Jingyu Li; Jingyi Zhao; Yu-Quan Wei; Carl K Edwards
Journal:  Sci Rep       Date:  2016-04-14       Impact factor: 4.379

Review 3.  Inflammation and cancer.

Authors:  Nitin Singh; Deepak Baby; Jagadish Prasad Rajguru; Pankaj B Patil; Savita S Thakkannavar; Veena Bhojaraj Pujari
Journal:  Ann Afr Med       Date:  2019 Jul-Sep

4.  Tumor Arrests DN2 to DN3 Pro T Cell Transition and Promotes Its Conversion to Thymic Dendritic Cells by Reciprocally Regulating Notch1 and Ikaros Signaling.

Authors:  Ipsita Guha; Avishek Bhuniya; Divanshu Shukla; Ashok Patidar; Partha Nandi; Akata Saha; Shayani Dasgupta; Nilanjan Ganguly; Sweta Ghosh; Arathi Nair; Subrata Majumdar; Bhaskar Saha; Walter J Storkus; Rathindranath Baral; Anamika Bose
Journal:  Front Immunol       Date:  2020-06-05       Impact factor: 7.561

Review 5.  Tumor promoting roles of IL-10, TGF-β, IL-4, and IL-35: Its implications in cancer immunotherapy.

Authors:  Bhalchandra Mirlekar
Journal:  SAGE Open Med       Date:  2022-01-25

6.  Increased serum level of interleukin-6 correlates with negative prognostic factors in extranodal NK/T-cell lymphoma.

Authors:  Changqian Bao; Lixia Zhu; Wenbin Qian; Xiujin Ye
Journal:  Transl Cancer Res       Date:  2020-04       Impact factor: 1.241

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.